UCR Study Finds E-Cig Aerosol Triggers Precancerous Lung Changes
“These findings are particularly concerning because squamous metaplasia can be a precursor to squamous cell carcinoma, a type of lung cancer,” said Prue Talbot, professor of the graduate division at the University of California, Riverside.
Her laboratory has built a new laboratory model that shows how electronic cigarette aerosols injure human airway tissue, in a study published in 2026 in NAM Journal.
The model, called hTET-AIR — human Tracheobronchial Epithelial Tissue–Airway Injury and Remodeling — combines a long-established lab-grown human airway tissue model with selected endpoints that track airway injury and remodeling over time. News-Medical reported the findings this week, drawing on a University of California, Riverside release; the peer-reviewed paper is available at NAM Journal.
What makes the work matter is its precision. Rather than inferring harm from animal studies or cell cultures that poorly mimic the lung lining, the Riverside team exposed donor-derived human airway tissue to realistic doses of e-cigarette aerosol and measured pathological change as it developed.
- Repeated e-cigarette aerosol exposure triggered mucus overproduction and squamous metaplasia in human airway tissue within the first week of a three-week experiment.
- Five puffs per day accelerated the damage compared with one puff per day, but both groups developed squamous metaplasia by week three.
- Squamous metaplasia is considered a potential precursor to squamous cell carcinoma, a form of lung cancer.
Why airway repair cells matter
The study rests on donor-derived human airway basal stem cells, which line the windpipe and the airways of the lungs. These cells act as the epithelium’s repair crew: they replace damaged cells, maintain the airway lining, and differentiate into mucus-producing cells and the ciliated cells that clear mucus and trapped particles, according to the University of California, Riverside summary carried by News-Medical.
That repair capacity is exactly what chronic aerosol exposure appears to disrupt. When the normal lining is repeatedly injured, the tissue remodels — and remodeling, not acute toxicity, is the process most closely tied to long-term morbidity in airway disease.
How the hTET-AIR model works
“The hTET-AIR model is equivalent to the tissue lining the human trachea and bronchus and can be exposed to aerosols at the air-liquid interface,” said Rattapol Phandthong, a postdoctoral researcher in UCR’s Department of Molecular, Cell and Systems Biology and first author of the study, in the university release reported by News-Medical.
Exposure at the air-liquid interface is the technical key. It means the tissue breathes aerosol from above, as a real airway does, rather than being submerged in a liquid dose — a methodological distinction that separates this model from older in vitro approaches.
“Building on this established model, our team developed the hTET-AIR to quantitatively evaluate the severity and progression of pathological changes in human airway tissue,” Phandthong said. “Beyond electronic cigarettes, hTET-AIR could also be applied to study the effects of other inhaled chemicals and environmental pollutants.”
The hTET model itself has been used in research laboratories for years to study how inhaled substances affect the respiratory tract, News-Medical reported. The new contribution is the endpoint selection that turns qualitative observation into quantitative scoring of injury severity and progression.
One puff versus five: what three weeks showed
The researchers exposed human airway tissues to either one or five puffs of e-cigarette aerosol per day for up to three weeks. Two pathological changes appeared as early as the first week in both groups.
The first was increased mucus production — goblet cell hyperplasia, in which the number of mucus-producing goblet cells rises in the respiratory epithelial lining. The second was squamous metaplasia, a transformation in which the airway’s usual lining takes on a skin-like character, undermining its capacity to sweep away mucus and inhaled particles.
| Exposure level | Pathological changes | Timing | Outcome by week three |
|---|---|---|---|
| One puff per day | Goblet cell hyperplasia; squamous metaplasia | Onset in the first week | Varying degrees of squamous metaplasia |
| Five puffs per day | Same changes, accelerated | Onset in the first week | Varying degrees of squamous metaplasia |
Dose mattered for speed, not direction. According to the study, the pathological changes progressed faster at five puffs per day than at one puff per day, yet by week three each exposure group had developed squamous metaplasia to varying degrees. The clinical implication is uncomfortable: low-level daily exposure did not spare the tissue, it only delayed the remodeling.
Funding and the team behind it
Grants from the UCR Academic Senate and the California Institute for Regenerative Medicine funded the work — the funding sources are disclosed alongside the paper, a transparency point worth noting in a research field where industry support is a persistent concern.
Talbot and Phandthong were joined by Edgar Rolon, Brianna Ramirez, Mohamad Kudsi, Audrey Choi, Arash Tahmasbi, Teresa Martinez, Wentai Luo, and Kevin McWhirter, per the study’s author list in NAM Journal.
Where the research goes next
The team plans to expand hTET-AIR to evaluate aerosols from additional e-cigarette devices and to examine responses in airway tissues derived from multiple donors. Phandthong said the aim is to establish whether varying degrees of airway damage result from different electronic cigarette products, and whether susceptibility differs from one person to another.
That susceptibility question is where the model could change clinical practice. If donor tissues from different people respond differently to identical aerosol exposure, the same framework could eventually help identify which users face the highest risk — a precision-medicine angle that current population-level studies of e-cigarettes cannot deliver.
For now, the findings land in a regulatory and clinical environment still debating how to counsel patients who vape.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.